Loading clinical trials...

One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNANCT06618313

One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL

Evaluate the Safety and Efficacy of JCXH-213 in Patients with Relapsed/Refractory B-cell non-Hodgkin Lymphoma

Lead sponsor: Beijing GoBroad Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Kai Hu

CONTACT

+86 15810245863 HK13610956245@163.com

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment8

Start dateMar 2025

Last updatedJun 3, 2025

Condition

B-Cell Non-Hodgkin Lymphoma-Recurrent B-Cell Non-Hodgkin Lymphoma-Refractory

Locations shown

Department of Lymphoma and Myeloma, Yuhengnan Road, Changping District, Beijing

Beijing

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 3, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions